Gh Research PLC (GHRS) — 6-K Filings

All 6-K filings from Gh Research PLC. Browse 42 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (42)

GH Research PLC Files Routine 6-K Report with SEC — Mar 25, 2026
GH Research PLC filed a 6-K on March 25, 2026, which is a routine report for foreign private issuers. This specific filing includes three exhibits: the 6-K itse
6-K Filing — Nov 24, 2025
GH Research to Present at Stifel Healthcare Conference — Nov 7, 2025 Risk: low
GH Research PLC announced its participation in the Stifel 2025 Healthcare Conference, taking place in New York from November 11-13, 2025. The company will engag
6-K Filing — Nov 6, 2025
GH Research PLC Trial Data Accepted at ACNP Meeting — Oct 17, 2025 Risk: low
GH Research PLC announced on October 17, 2025, that abstracts related to its GH001-TRD-201 clinical trial have been accepted for presentation at the 64th Americ
GH Research Presents GH001-TRD-201 Trial Data at ECNP Meeting — Oct 14, 2025 Risk: medium
GH Research PLC announced on October 14, 2025, that data from its GH001-TRD-201 clinical trial was presented at the 38th European College of Neuropsychopharmaco
GH Research to Present Clinical Trial Data at ECNP Meeting — Oct 10, 2025 Risk: low
GH Research PLC announced on October 10, 2025, that data from its GH001-TRD-201 clinical trial will be presented at the 38th European College of Neuropsychophar
GH Research to Present at ECNP Meeting — Oct 9, 2025 Risk: low
GH Research PLC announced its participation in the 38th European College of Neuropsychopharmacology (ECNP) annual meeting, scheduled for October 11-14, 2025, in
GH Research to Present at TD Cowen Neuropsychiatry Summit — Sep 12, 2025 Risk: low
GH Research PLC announced its participation in the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry and Epilepsy Summit. The company will present during
GH Research to Present Bipolar Trial Data at ISBD Meeting — Sep 9, 2025 Risk: low
GH Research PLC announced on September 9, 2025, that data from its GH001-BD-202 clinical trial will be presented at the International Society for Bipolar Disord
GH Research to Present at Cantor Global Healthcare Conference — Aug 29, 2025 Risk: low
GH Research PLC announced its participation in the Cantor Global Healthcare Conference, scheduled for September 3-5, 2025, in New York. The company will engage
GH Research PLC Files 6-K with Financial Updates — Aug 7, 2025 Risk: low
GH Research PLC filed a 6-K report on August 7, 2025, for the period ending June 30, 2025. The filing includes financial data for the periods ending December 31
GH Research PLC Annual Meeting: All Resolutions Passed — Aug 1, 2025 Risk: low
GH Research PLC held its annual general meeting on July 31, 2025, where shareholders approved all resolutions recommended by the board of directors. Notably, Fl
GH Research PLC Announces Pivotal Program Plans — Jul 23, 2025 Risk: medium
On July 23, 2025, GH Research PLC announced its global pivotal program plans and provided further development updates. The company filed a Form 6-K to report th
GH Research PLC Responds to FDA Clinical Hold for GH001 — Jun 20, 2025 Risk: medium
On June 20, 2025, GH Research PLC announced it submitted a complete response to the FDA regarding the clinical hold on its Investigational New Drug Application
GH Research PLC Schedules Annual General Meeting for July 31 — Jun 18, 2025 Risk: low
GH Research PLC announced on June 18, 2025, a convening notice for its annual general meeting. The meeting is scheduled for July 31, 2025, at 2:00 PM Irish Stan
GH Research to Participate in Neuro Perspectives Conference — Jun 13, 2025 Risk: low
GH Research PLC announced its participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, scheduled for June 16-17, 2025. The company
GH Research to Present at ASCP Annual Meeting — May 27, 2025 Risk: low
GH Research PLC announced its participation in the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, held from May 27-30, 2025, in Scottsda
GH Research to Present at ASCP Annual Meeting — May 21, 2025 Risk: low
GH Research PLC announced on May 21, 2025, that it will attend the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting from May 27-30, 2025, i
GH Research PLC Accepted to ASCP Annual Meeting — May 15, 2025 Risk: low
GH Research PLC announced on May 15, 2025, that its pharmaceutical pipeline presentations and late-breaking posters have been accepted at the American Society o
GH Research PLC Files Q1 2025 6-K Report — May 8, 2025 Risk: low
GH Research PLC filed a 6-K report for the period ending March 31, 2025. The filing includes financial data for the first quarter of 2025 and the full year 2024
GH Research PLC Completes Share Offering — Feb 6, 2025 Risk: medium
On February 6, 2025, GH Research PLC completed an offering of 10,000,000 ordinary shares. This offering was conducted under an underwriting agreement with Canto
GH Research Prices $150M Public Offering — Feb 5, 2025 Risk: medium
GH Research PLC announced on February 4, 2025, the pricing of a public offering of its ordinary shares, raising $150 million. The offering is expected to close
GH Research PLC's GH001 Meets Primary Endpoint in TRD Trial — Feb 3, 2025 Risk: medium
On February 3, 2025, GH Research PLC announced that its product candidate, GH001, an inhalable mebufotenin, met its primary endpoint in a Phase 2b clinical tria
GH Research Plans Public Share Offering — Feb 3, 2025 Risk: medium
GH Research PLC announced a proposed public offering of its ordinary shares on February 3, 2025. The company, headquartered in Dublin, Ireland, is a foreign pri
GH Research PLC Files 6-K, Updates GH001 Trial — Jan 31, 2025 Risk: medium
GH Research PLC filed a 6-K report on January 31, 2025, announcing an update on its Phase 2b trial for GH001. The company, headquartered in Dublin, Ireland, is
GH Research PLC's GH001 Meets Phase 2a Endpoints, FDA Hold Addressed — Jan 10, 2025 Risk: medium
On January 10, 2025, GH Research PLC announced that its drug candidate GH001 met its primary endpoint in two Phase 2a Proof-of-Concept (POC) trials. The company
GH Research to Attend Neuropsychopharmacology Meeting — Dec 5, 2024 Risk: low
GH Research PLC announced on December 5, 2024, that it will participate in the 63rd Annual Meeting of the American College of Neuropsychopharmacology 2024. The
GH Research PLC Files 6-K with Q3 2024 Financials — Nov 14, 2024 Risk: low
GH Research PLC filed a 6-K report on November 14, 2024, detailing financial information as of September 30, 2024. The filing includes comparative balance sheet
GH Research PLC to Present at 37th ECNP Congress — Sep 20, 2024 Risk: low
GH Research PLC announced its attendance at the 37th ECNP Congress in Milan, Italy, from September 21-24, 2024. The company will sponsor an industry mini-sessio
GH Research to Present at Cantor Global Healthcare Conference — Sep 16, 2024 Risk: low
GH Research PLC announced its participation in the Cantor Global Healthcare Conference, scheduled for September 17-19, 2024, in New York. The company will engag
GH Research to Present at H.C. Wainwright Conference — Sep 9, 2024 Risk: low
GH Research PLC announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, taking place from September 9-11, 2024, in New York
GH Research PLC Files 6-K with Financial Updates — Sep 3, 2024 Risk: low
GH Research PLC filed a 6-K report on September 3, 2024, detailing financial information for the period ending June 30, 2024. The filing includes balance sheet
GH Research PLC Shareholders Approve All Board Resolutions — Jun 28, 2024 Risk: low
On June 27, 2024, GH Research PLC held its annual general meeting where shareholders approved all resolutions recommended by the board of directors. The company
GH Research PLC to Present at Two Healthcare Conferences — Jun 24, 2024 Risk: low
GH Research PLC announced on June 24, 2024, that it will participate in investor meetings at the Stifel European Healthcare Summit in Lyon, France, from June 25
GH Research PLC Schedules Annual General Meeting for June 27 — May 15, 2024 Risk: low
GH Research PLC announced on May 15, 2024, a convening notice for its annual general meeting scheduled for June 27, 2024, at 2:00 p.m. Irish Standard Time in Du
GH Research PLC Q1 2024 6-K Filing — May 3, 2024 Risk: low
GH Research PLC filed a 6-K report for the period ending March 31, 2024. The filing includes financial data for the first quarter of 2024 and the full year 2023
GH Research to Attend Life Sciences Conference — Apr 10, 2024 Risk: low
GH Research PLC announced on April 10, 2024, that it will participate in Van Lanschot Kempen's Life Sciences Conference in Amsterdam from April 16-17, 2024. The
GH Research to Participate in Stifel Virtual CNS Days — Mar 15, 2024 Risk: low
GH Research PLC announced its participation in the Stifel 2024 Virtual CNS Days, scheduled for March 19-20, 2024. The company will engage in a fireside chat and
GH Research to Present at TD Cowen Health Care Conference — Feb 29, 2024 Risk: low
GH Research PLC announced on February 29, 2024, that it will participate in the 44th Annual TD Cowen Health Care Conference from March 4-6, 2024, in Boston, Mas
GH Research Secures European Patent for Mebufotenin in Depression — Jan 18, 2024
GH Research PLC, a clinical-stage biopharmaceutical company, announced on January 18, 2024, that the European Patent Office (EPO) granted them a patent (EP39273
GH Research to Host Investor Meetings at J.P. Morgan Healthcare Conference — Jan 5, 2024
GH Research PLC announced on January 5, 2024, that it will be holding one-on-one investor meetings at the 42nd Annual J.P. Morgan Healthcare Conference from Jan

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX